Literature DB >> 14729877

Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans.

Nicolas Moniaux1, Grish Chandra Varshney, Subhash Chand Chauhan, Marie Christine Copin, Maneesh Jain, Uwe A Wittel, Mahefatiana Andrianifahanana, Jean-Pierre Aubert, Surinder Kumar Batra.   

Abstract

We have previously cloned the full-length cDNA (approximately 28 Kb) and established the complete genomic organization (25 exons/introns over 100 kb) of the human MUC4 mucin. This large molecule is predicted to protrude over 2 microm above the cell surface, in which MUC4alpha is an extracellular mucin-type glycoprotein subunit and MUC4beta is the transmembrane subunit. Over two thirds of the encoded protein sequence consists of 16-amino-acid tandem repeats (TR), which are flanked by unique sequences. In this study we generated and characterized monoclonal antibodies (MAbs) directed against the TR region of MUC4. Mice were immunized with a KLH-conjugated MUC4 TR peptide, STGDTTPLPVTDTSSV. Several clones were purified by three rounds of limited dilutions and stable clones presenting a sustained antibody production were selected for subsequent characterization. Antibodies were tested for their reactivity and specificity to recognize the MUC4 peptide and further screened by enzyme-linked immunosorbent assay (ELISA) and Western blotting analyses. One of the MAbs (8G7) was strongly reactive against the MUC4 peptide and with native MUC4 from human tissues or pancreatic cancer cells in Western blotting, immunohistochemistry, and confocal analysis. Anti-MUC4 MAb may represent a powerful tool for the study of MUC4 function under normal and pathological conditions and for diagnosis of solid tumors including those in the breast, pancreas, lungs, and ovaries.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14729877     DOI: 10.1177/002215540405200213

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  50 in total

Review 1.  Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy.

Authors:  Partha Mukhopadhyay; Subhankar Chakraborty; Moorthy P Ponnusamy; Imayavaramban Lakshmanan; Maneesh Jain; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2011-01-26

2.  Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies.

Authors:  Maria P Torres; Moorthy P Ponnusamy; Subhankar Chakraborty; Lynette M Smith; Srustidhar Das; Hwyda A Arafat; Surinder K Batra
Journal:  Mol Cancer Ther       Date:  2010-04-27       Impact factor: 6.261

3.  Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.

Authors:  Albert C Chen; Ilenia Migliaccio; Mothaffar Rimawi; Sara Lopez-Tarruella; Chad J Creighton; Suleiman Massarweh; Catherine Huang; Yen-Chao Wang; Surinder K Batra; M Carolina Gutierrez; C Kent Osborne; Rachel Schiff
Journal:  Breast Cancer Res Treat       Date:  2012-05-29       Impact factor: 4.872

4.  Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering.

Authors:  Gufeng Wang; Robert J Lipert; Maneesh Jain; Sukhwinder Kaur; Subhankar Chakraboty; Maria P Torres; Surinder K Batra; Randall E Brand; Marc D Porter
Journal:  Anal Chem       Date:  2011-03-10       Impact factor: 6.986

5.  Generation and Identification of Peptide-Based Monoclonal Antibodies Against Vacuolar Proton Pyrophosphatase of Toxoplasma gondii.

Authors:  Chengbi Tong; Bin Xiao; Shasha Cheng; Wei Li; Xiaoqing Liao; Shuhong Luo; Wenbo Hao
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-06

6.  Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism.

Authors:  María P Torres; Satyanarayana Rachagani; Vinee Purohit; Poomy Pandey; Suhasini Joshi; Erik D Moore; Sonny L Johansson; Pankaj K Singh; Apar K Ganti; Surinder K Batra
Journal:  Cancer Lett       Date:  2012-04-01       Impact factor: 8.679

7.  MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.

Authors:  Pallavi Chaturvedi; Ajay P Singh; Subhankar Chakraborty; Subhash C Chauhan; Sangeeta Bafna; Jane L Meza; Pankaj K Singh; Michael A Hollingsworth; Parmender P Mehta; Surinder K Batra
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

8.  Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance.

Authors:  Elizabeth G Munro; Maneesh Jain; Esther Oliva; Neel Kamal; Subodh M Lele; Maureen P Lynch; Lankai Guo; Kai Fu; Poonam Sharma; Steve Remmenga; Whitfield B Growdon; John S Davis; Bo R Rueda; Surinder K Batra
Journal:  Int J Gynecol Pathol       Date:  2009-03       Impact factor: 2.762

9.  Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer.

Authors:  Neeley Remmers; Judy M Anderson; Erin M Linde; Dominick J DiMaio; Audrey J Lazenby; Hans H Wandall; Ulla Mandel; Henrik Clausen; Fang Yu; Michael A Hollingsworth
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

Review 10.  Review of the adenocarcinoma cell surface receptor for human alpha-fetoprotein; proposed identification of a widespread mucin as the tumor cell receptor.

Authors:  G J Mizejewski
Journal:  Tumour Biol       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.